文献速递浆细胞疾病

MALDI-TOF质谱检测外周血可测量残留活动在新诊断多发性骨髓瘤中的评估:III期GMMG-HD7试验

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
PubMed 文献 · J Clin Oncol · 2026-05-21

该研究分析III期GMMG-HD7试验中617例新诊断多发性骨髓瘤患者的3301份血清样本,评估MALDI-TOF质谱检测单克隆蛋白的分析性能与临床价值。质谱可靠区分治疗性抗体、纵向追踪诊断性M蛋白,并显示强预后价值:质谱阴性者无进展生存期(PFS)更优,维持治疗12个月时风险比0.25(95%CI 0.15-0.43;质谱与骨髓可测量残留病(MRD)联合评估可细化风险分层,质谱/MRD双阳性患者PFS最差。

要点

  • 质谱与骨髓MRD联合评估可细化风险分层,双阳性者PFS最差。
  • 质谱在低浓度下优于血清蛋白电泳,可准确定量低水平残留病。

核心结论

  • 血清质谱是敏感、可重复且实用的生物标志物,可补充MRD并支持微创疾病监测。
  • 质谱阴性提示PFS更优,后期时间点分离最大。
  • 质谱/MRD双阳性患者PFS最差,其他组结局相近。

研究设计与样本

  • 基于III期GMMG-HD7试验的前瞻性分析,纳入617例新诊断多发性骨髓瘤患者。
  • 共分析3301份血清样本,评估MALDI-TOF质谱检测可测量残留活动的分析性能与临床相关性。

主要发现

  • 质谱可靠区分治疗性抗体,并纵向追踪诊断性M蛋白。
  • 质谱/MRD联合评估细化风险分层:双阳性者PFS最差,其他组结局相近。
  • 质谱/MRD一致性随时间增加,受免疫球蛋白同种型影响,IgG再循环相关早期不一致符合预期。
  • 质谱在低浓度下优于血清蛋白电泳,可可靠定量低水平残留病。

临床怎么用

  • 血清质谱可作为微创监测工具,补充骨髓MRD评估多发性骨髓瘤残留病。
  • 联合质谱与MRD可识别PFS最差的双阳性高危患者,辅助风险 Adapted 治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mass spectrometry (MS) offers a minimally invasive approach for detecting monoclonal proteins in multiple myeloma (MM), but large prospective evaluations remain limited. We analyzed 3,301 serum samples from 617 patients enrolled in the phase III GMMG-HD7 trial to characterize the analytical performance and clinical relevance of MS-based measurable residual activity. MS reliably distinguished therapeutic antibodies, tracked diagnostic M proteins longitudinally, and demonstrated strong prognostic value across defined time points. MS negativity was associated with superior progression-free survival (PFS), with the greatest separation at later time points (12 months of maintenance: hazard ratio, 0.25 [95% CI, 0.15 to 0.43]; adjusted P < .001). Combined assessment with bone-marrow measurable residual disease (MRD) further refined risk stratification: MS/MRD double-positive patients exhibited the worst PFS, whereas all other groups showed comparably favorable outcomes. MS/MRD concordance increased over time and was influenced by immunoglobulin isotype, with expected immunoglobulin G-recycling-associated early discordance. MS provided accurate M-protein detection and outperformed serum protein electrophoresis at low concentrations, reliably quantifying low-level residual disease. These findings establish serum MS as a sensitive, reproducible, and practical biomarker that complements MRD and supports minimally invasive disease monitoring in MM, with potential integration into future response assessment and risk-adapted treatment strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jin JX, Ginde VR, Huhn S, et al. Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial. J Clin Oncol. 2026. PMID: 42166704. doi:10.1200/JCO-25-02957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。